The decision comes just weeks after HSD bagged a UK med ed brief for Solaraze (PRWeek, 13 January) – a treatment for actinic
keratosis, a precursor to skin cancer.
Resolute was involved in a head-to-head pitch against HSD for the PR contract. Its joint CEO Paul Blackburn said: 'We believe we have set a benchmark for awareness of actinic keratosis and wish HSD success.'
NICE released guidance on skin cancer treatment just last month.
The rolling of the entire UK brief into HSD completes a multi-stage brand review that kicked off in the middle of last year.
Resolute continues to handle international work for Shire on the brand.
keratosis, a precursor to skin cancer.
Resolute was involved in a head-to-head pitch against HSD for the PR contract. Its joint CEO Paul Blackburn said: 'We believe we have set a benchmark for awareness of actinic keratosis and wish HSD success.'
NICE released guidance on skin cancer treatment just last month.
The rolling of the entire UK brief into HSD completes a multi-stage brand review that kicked off in the middle of last year.
Resolute continues to handle international work for Shire on the brand.
